

# MDA-MB-231 TetOn-3G MRCKBeta cell line

**Catalogue number:** 154149

**Sub-type:** Continuous

**Images:**

## Contributor

**Inventor:** Daniel Croft ; Justin Bower ; Heather Mckinnon

**Institute:** Cancer Research UK, Glasgow: The Beatson Institute

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** MDA-MB-231 TetOn-3G MRCKBeta cell line

**Alternate name:** Serine/threonine-protein kinase MRCK beta, CDC42-binding protein kinase beta, CDC42BP-beta, DMPK-like beta, Myotonic dystrophy kinase-related CDC42-binding kinase beta, MRCK beta, Myotonic dystrophy protein kinase-like beta

**Class:**

**Conjugate:**

**Description:** This cell line has been engineered to enable tetracycline inducible expression of the kinase MRCK $\beta$ . MRCK $\beta$  is a myotonic dystrophy kinase-related CDC42-binding kinase involved in regulating actin-myosin contractility and implicated in cancer metastasis. MRCK $\beta$ , in conjunction with MRCK $\alpha$ , ROCK1 and ROCK2 kinases, initiates signalling events that lead to contractile force generation which powers cancer cell motility and invasion. The cell line is a derivative of a human breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Useful for the study of breast cancer cell cytoskeleton reorganisation and cell migration. This cell line is derived from a triple negative breast cancer (TNBC) meaning it does not express oestrogen, progesterone or HER2 receptors. Treatment with doxycycline induced MRCK $\beta$  kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested.

**Purpose:**

**Parental cell:** MDA-MB-231 D3H2LN-Luc cell line

**Organism:** Human

**Tissue:** Breast

**Model:** Transgenic

**Gender:**

**Isotype:**

**Reactivity:**

**Selectivity:**

**Host:**

**Immunogen:**

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:** Adherent cell line. Membrane blebbing/cytoskeleton reorganisation and migration induced in the presence of doxycycline.

**Production details:**

**Formulation:**

**Recommended controls:** MDA-MB-231 D3H2LN-Luc parental line

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:** Treatment with doxycycline induced MRCK? kinase domain expression and resulted in increased MLC phosphorylation. Clone demonstrated profound membrane blebbing following doxycycline treatment. Transgene expression did not appear to be 'leaky' in any clones tested. Tet-On System owned by TET Systems GmbH & Co. KG.

## Target details

**Target:** MRCK

**Target alternate names:**

**Target background:**

**Molecular weight:**

**Ic50:**

## Applications

**Application:**

**Application notes:**

## Handling

**Format:** Frozen

**Concentration:**

**Passage number:**

**Growth medium:** 10% FBS/MEM-EBSS/NEAA/NaPyr/Glutamine

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:**

**Storage conditions:** Liquid Nitrogen

**Shipping conditions:** Dry ice

## Related tools

**Related tools:**

## References

**References:**

CancerTools.org